表 1.
脑膜转移癌患者基线特征
Clinical features of baseline patients with leptomeningeal metastases
| Variables | Total | Experiment group (n=52) | Control group (n=53) | P |
| EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase. | ||||
| Age (yr) | 53.81±8.18 | 53.84±8.59 | 53.79±7.76 | 0.889 |
| Gender | 0.481 | |||
| Male | 31 (29.52%) | 17 (32.69%) | 14 (26.42%) | |
| Female | 74 (70.48%) | 35 (67.31%) | 39 (73.59%) | |
| Headache | 81 (77.14%) | 43 (82.69%) | 38 (71.70%) | 0.180 |
| Sick and vomit | 58 (55.24%) | 36 (69.23%) | 22 (41.51%) | 0.004 |
| Vision loss | 42 (40.00%) | 18 (34.62%) | 24 (45.28%) | 0.265 |
| Hearing loss | 36 (34.29%) | 16 (30.77%) | 20 (37.74%) | 0.452 |
| Movement disorder | 53 (50.48%) | 22 (42.31%) | 31 (58.49%) | 0.097 |
| Confusion | 13 (12.38%) | 7 (13.46%) | 6 (11.32%) | 0.739 |
| Previous chemotherapy | 83 (79.05%) | 37 (71.15%) | 46 (86.79%) | 0.049 |
| Previous radiotherapy | 53 (50.48%) | 30 (57.69%) | 23 (43.40%) | 0.143 |
| Targeted therapy | 94 (89.52%) | 43 (82.69%) | 51 (96.23%) | 0.024 |
| EGFR exon 19 mutation | 23 (21.91%) | 6 (11.54%) | 17 (32.08%) | 0.011 |
| EGFR exon 21 mutation | 36 (34.29%) | 18 (34.62%) | 18 (33.96%) | 0.944 |
| ALK fusion mutation | 16 (15.24%) | 8 (15.39%) | 8 (15.10%) | 0.967 |
| Only leptomeningeal metastases | 52 (49.52%) | 29 (55.77%) | 23 (43.40%) | 0.714 |
| Combined with brain metastases | 29 (27.62%) | 15 (28.85%) | 14 (26.42%) | 0.395 |
| Cerebrospinal fluid pressure (mmH2O) | ||||
| < 200 | 62 (59.05%) | 32 (61.54%) | 30(56.6%) | 0.607 |
| ≥200 | 43 (40.95%) | 20 (38.46%) | 23(43.40%) | |